AveXis

AveXis. A pioneering American biotechnology company focused on developing novel treatments for rare neurological genetic disorders, most notably spinal muscular atrophy (SMA). Founded in 2010, the company rapidly advanced a groundbreaking adeno-associated virus (AAV)-based gene therapy, which culminated in its acquisition by the global pharmaceutical giant Novartis for $8.7 billion. AveXis's work represents a landmark achievement in the field of gene therapy, bringing a transformative one-time treatment to patients with a previously devastating condition.

History

AveXis was established in 2010 by neuroscientist Brian Kaspar, his brother Allan Kaspar, and executive John T. Gray, with foundational research originating at the Nationwide Children's Hospital in Columbus, Ohio. The company's initial mission centered on leveraging AAV9, a specific serotype of the adeno-associated virus, to deliver functional genes directly to the central nervous system. In 2014, the company secured substantial venture capital funding from investors like Fidelity Investments and Deerfield Management to advance its lead candidate. A pivotal moment occurred in 2016 when Sean Nolan, formerly of InterMune, joined as CEO, providing seasoned leadership to guide the firm through critical clinical and regulatory phases. The company's promising data attracted the attention of Novartis, leading to a definitive acquisition agreement announced in April 2018.

Products and development

The company's flagship product, later commercialized as Zolgensma, was an investigational gene therapy designed to treat spinal muscular atrophy Type 1, the most severe form of the disease caused by mutations in the SMN1 gene. The therapy utilized a bioengineered adeno-associated virus vector to deliver a fully functional copy of the human SMN1 gene to target motor neuron cells. This approach aimed to address the genetic root cause of SMA by enabling sustained production of the essential survival motor neuron protein. The development program was supported by preclinical work conducted in collaboration with researchers at the Ohio State University and built upon earlier scientific discoveries from laboratories like those of Arthur Burghes and the University of Oxford.

Clinical trials and approvals

AveXis initiated its first clinical study, the Phase 1 START trial, in 2014, with results presented at meetings of the American Academy of Neurology demonstrating remarkable efficacy and a favorable safety profile. This was followed by the larger, pivotal Phase 3 STR1VE trial conducted in the United States and the Phase 3 SPR1NT trial. The compelling clinical data, showing unprecedented survival and milestone achievement compared to the natural history of the disease, formed the basis for regulatory submissions. Under the stewardship of Novartis, the therapy gained accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2019, followed by endorsements from the European Medicines Agency and Japan's Pharmaceuticals and Medical Devices Agency.

Corporate affairs

Prior to its acquisition, AveXis was headquartered in Bannockburn, Illinois, and operated a state-of-the-art commercial manufacturing facility in Libertyville, Illinois. The $8.7 billion acquisition by Novartis, one of the largest ever in the gene therapy sector, was completed in June 2018. Following the acquisition, the unit was integrated into Novartis Gene Therapies, with former AveXis President David Lennon assuming a key leadership role. The company navigated significant regulatory scrutiny from the FDA regarding data accuracy in its Biologics License Application, which resulted in a settlement with the U.S. Securities and Exchange Commission related to disclosure controls.

Impact and reception

The development and approval of AveXis's therapy, Zolgensma, marked a paradigm shift in the treatment of spinal muscular atrophy and the broader field of genetic disorders. It offered a one-time, potentially curative alternative to chronic treatments like Biogen's Spinraza. The therapy's high list price, exceeding $2 million, sparked intense debate about healthcare economics, value-based pricing, and patient access, involving policymakers, insurers, and advocacy groups like Cure SMA. The scientific achievement was recognized with awards such as the Prix Galien USA Award for Best Biotechnology Product, cementing its status as a landmark advancement in modern medicine.

Category:Biotechnology companies of the United States Category:Gene therapy Category:Novartis